December 1, 2021 -- Northwest Biotherapeutics, a biotechnology company developing DCVax personalized immune therapies for solid tumor cancers, has secured $15 million in financing to accelerate its brain cancer program.
The financing is in the form of a 22-month loan which requires no payments for eight months followed by a 14-month amortization period.
Northwest is developing platform technology for its DCVax dendritic cell-based vaccines. These personalized immunotherapy products are designed to treat cancers without the toxicities that are associated with chemotherapies. DCVaxI has completed a 40-patient phase I trial for inoperable solid tumors, and the company is planning to pursue a phase II trial next.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
